Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Authors
Ray McDermott (ORCID: https://orcid.org/0000-0002-8952-4315)
Nuria Sala Gonzalez
Emmanuel S. Antonarakis (ORCID: https://orcid.org/0000-0003-0031-9655)
Jeffrey C. Goh (ORCID: https://orcid.org/0000-0003-3103-146X)
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Ray McDermott, Nuria Sala Gonzalez, Emmanuel S. Antonarakis, Jeffrey C. Goh et al.
Citations
2 citations
Journal
European Urology Oncology
Topics
Prostate Cancer Treatment and Research
Field-Weighted Citation Impact (FWCI)
3.04
article
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Ray McDermott, Nuria Sala Gonzalez, Emmanuel S. Antonarakis, Jeffrey C. Goh, Felipe Rey, Niven Mehra, Richard Greil, Patricio Yañez, Peter C.C. Fong, Se Hoon Park, Christian Hosius, Eric Yi‐Hsiu Huang, Todd L. Saretsky, Yi Ping Cui, Gero Kramer, Sameer R. Ghate, Stephen Begbie, Evan Y. Yu, Maria De Santis, Hiroyoshi Suzuki
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
European Urology OncologyVol. 8(4)
Institutions
Universidad de La Frontera (CL), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Toho University (JP), Radboud University Nijmegen (NL), National Yang Ming Chiao Tung University (TW), University of Auckland (NZ), University of Washington (US), Paracelsus Medical University (AT), Royal Brisbane and Women's Hospital (AU), Auckland City Hospital (NZ), Samsung Medical Center (KR), Radboud University Medical Center (NL), Taipei Veterans General Hospital (TW), Fred Hutch Cancer Center (US), Centro de Investigación y Desarrollo (ES), Cancer Trials Ireland (IE), MSD (Germany) (DE), Toho University Medical Center Sakura Hospital (JP), Port Macquarie Base Hospital (AU), Hospital Universitari de Girona Doctor Josep Trueta (ES), Sidney Kimmel Comprehensive Cancer Center (US), Medical University of Vienna (AT), Charité - Universitätsmedizin Berlin (DE)